Nasopharyngeal Neoplasms Clinical Trial
Official title:
Camrelizumab (PD-1 Antibody) Compared With Best Supportive Care After Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: a Multi-center, Randomised Controlled, Phase 3 Trial (DIPPER)
This trial is aimed to investigate whether adjuvant PD-1 antibody treatment could improve survival in locoregionally advanced nasopharyngeal carcinoma compared to best supportive care.
In this multicenter, randomised controlled, phase 3 trial, patients with stage III-IVA (AJCC/UICC 8th system, except T3-4N0 and T3N1) non-metastatic nasopharyngeal carcinoma will be randomized in a 1:1 ratio to recieve PD-1 antibody for 12 doses every 3 weeks or best supportive care after curative chemoradiation. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01256853 -
Modified Vaccinia Ankara (MVA) Vaccine Study
|
Phase 1 | |
| Not yet recruiting |
NCT00577057 -
Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal Cancer
|
N/A | |
| Recruiting |
NCT02945878 -
Predictive Factors of Acute Oral Mucositis Induced by Chemo-radiotherapy for Local Advanced Nasopharyngeal Carcinoma
|
N/A | |
| Terminated |
NCT02874651 -
ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
|
Phase 2 | |
| Not yet recruiting |
NCT05807880 -
Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma
|
Phase 2 | |
| Completed |
NCT00342147 -
Family Study of Head and Neck Cancers in Taiwan
|
||
| Recruiting |
NCT02980315 -
A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01735409 -
Dose-finding Study of Abraxane in Combination With Cisplatin to Treat Advanced Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
| Completed |
NCT00565448 -
Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents
|
Phase 2 | |
| Completed |
NCT00630149 -
Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy
|
Phase 2 | |
| Active, not recruiting |
NCT03854838 -
IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.
|
Phase 2 | |
| Completed |
NCT01797900 -
The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT
|
Phase 2 | |
| Completed |
NCT00436800 -
Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT00563927 -
Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)
|
N/A | |
| Not yet recruiting |
NCT04870905 -
Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT02902432 -
A Trial of Endostar in Patients With Carcinoma of the Head and Neck
|
Phase 2 | |
| Active, not recruiting |
NCT02456506 -
Hyperfractionated Intensity-modulated Radiotherapy (IMRT) Versus Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma.
|
N/A | |
| Completed |
NCT02444949 -
A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma
|
Phase 2 | |
| Completed |
NCT00188877 -
Intensity Modulated Radiation Therapy for Head and Neck Cancer
|
Phase 2 | |
| Terminated |
NCT00393224 -
Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families
|